Biopharma CI is not just delayed.
It’s miscalibrated.
It’s measuring the wrong signals, asking the wrong questions, trusting the wrong voices.
Yes, it is uncomfortable to hear this from a consultant.
The real discomfort is that it already feels true.
This keynote is not a presentation.
It is a classified debrief on the failure points your team won’t see—until it’s too late:
• How “coverage” became the enemy of consequence
• How AI fluency produces coherence without truth
• How HUMINT grids now shape strategy before advisory boards convene
• Why velocity has replaced vigilance—and no one noticed
After this session, you will not look at CI the same way.
If you do, that’s the most dangerous signal of all.

While many of these headwinds are daunting, CI professionals are uniquely positioned to help their organizations anticipate market shifts, decode competitor strategy, and proactively mitigate risk. This session will explore the most critical industry challenges and offer actionable recommendations on how CI teams can deliver strategic value.

This presentation examines a systematic approach to resolving this paradox by deploying coordinated artificial intelligence agents that function as a specialized autonomous competitive intelligence team.
Drawing from implementation across multiple pharmaceutical organizations, we will analyze how this framework achieves sub-20-minute alert delivery while reducing operational expenditures by over fifty percent.
The session will provide insights into three core areas.
First, we will cover the principles underlying successful Autonomous AI Monitoring Systems that operate continuously across global markets and timezones.
Second, we will examine how these systems generate personalized stakeholder communications without human oversight.
Third, we will analyze the economic model that enables organizations to achieve substantial cost reductions while simultaneously improving both the speed and relevance of intelligence delivery.
Attendees will leave with a clear understanding of implementing, evaluating and optimizing AI-driven CI monitoring and alerts capabilities.

• Key elements of an excellent CI narrative with a clearly-articulated storyline, including how to win confidence as a narrator
• How a CI narrative with a clearly-articulated storyline elevates the value of CI by boosting engagement, comfort, connection, alignment and contribution
• How great storytelling “moves the needle” on critical objectives and amplifies strategic messages
• How to control your CI storyline across multi-functional stakeholders
• How to best use AI as part of this process

We will demonstrate how metrics such as market share shifts, revenue implications, and timeline effects empower faster, smarter, and more confident strategic decisions across the broader ecosystem.
Key Highlights:
• AI + expert-guided news analysis
• Clear impact quantification: market share, revenue, timelines
• Accelerated forecasting, planning, and strategic response
• Seamless integration into existing workflows, saving analyst hours

Agentic AI changes this dynamic. It empowers AI agents to autonomously recognize meaningful patterns, proactively uncover insights, and even recommend or execute strategic actions, all within predefined goals and guardrails established by human decision-makers.

In this engaging session, David Seuss, founder and CEO of Northern Light, will share practical examples of how Agentic AI is reshaping market research and competitive intelligence in pharma, empowering organizations to move beyond reacting to market changes toward actively driving strategic decisions. Mr. Seuss will illustrate how Agentic AI:

• Accelerates strategic responses to rapidly shifting market conditions.
• Enables highly personalized insights at scale.
• Streamlines competitive intelligence through autonomous monitoring and analysis of market dynamics.

However, the development and commercialization of biosimilars differ substantially from that of generic NMEs. As a result, modern biosimilar manufacturers must stay attuned to key market trends, technological advancements, shifting dynamics, and global collaborations.
This session will shed light on the tailored competitive intelligence (CI) needs of biosimilar companies and how they diverge from traditional approaches used in innovative drug development market monitoring. It aims to help biosimilar manufacturers reassess their essential CI requirements and build a compelling case for securing the necessary budget from leadership teams.

Furthermore, supply chain disruptions, drug pricing and reimbursement constraints, changes in regulations and policies, and volatility in biotech funding continue to impact the industry.

Meanwhile, China is emerging as a global innovation hub, with its biotech and pharmaceutical companies becoming key players in novel drug development and clinical trials with increased activity in licensing and partnership deals with international firms.

In GlobalData’s “The State of the Biopharmaceutical Industry with Spotlight on Drug Development in China” presentation, we will examine the key trends shaping the biopharmaceutical industry and the impact of pharmaceutical innovation in China.

• Regional share of total number of oncology trials and associated evolution from 2019 to 2024
• Spotlight on Europe; heat map of clinical trial growth verses a 2019 baseline – the Covid impact
• Illustrative country comparison; UK verses Romania
Analysis of data that is easily accessible that can help pharma business units and therapy area teams gain a competitive edge by conducting trials in geographies that others aren’t

The growing mindset is that AI can replicate rather than enable much of what these teams do—faster and cheaper. This poses a serious risk to the future of Market Research, Competitive Intelligence, and Consumer Insights roles unless professionals can demonstrate clear, measurable value.
Session Objectives:
1.Address the Threat Before It’s Too Late
Cut through the AI hype and confront the real risk: Automation is starting to put insights, research, and CI teams on the chopping block, and the fallout could come fast if you don’t act now.
2. Use a Proven Framework to Defend your Value
Leverage the ROCI® (Return on Competitive Intelligence) model to quantify your team’s impact, influence leadership decisions, and prove why humans still matter.
3. Walk Away with a Battle-Ready Strategy to Stay Indispensable
Get practical guidance and debate-style talking points to shift perceptions, secure executive support, future-proof your role, and protect your seat at the strategic table.

TRENDS: combination products to address side effects (muscle loss) & exciting new indications (MASH, addiction, etc); non Peptide GLP1s; the rise of China as a producer & innovator; new delivery systems
CHALLENGES: supply chain; manufacturing inefficiencies; geopolitics; market access; how to differentiate your GLP1.
OPPORTUNITIES: differentiation by combo products; development of new non Peptide GLP1 drug substances; drug delivery innovation; companion products in the medical device, food, nutrition, lifestyle space

Join us for a transparent deep dive into the engineering behind a next-generation AI for CI. Drawing on 18 months of focused development, we will share the hard-won lessons from building an engine that can reconstruct a competitor’s strategic playbook from public data. We will not be discussing a product, but rather the core methodologies for success, including designing complex task￾decomposition pipelines, managing inter-agent communication for synthesized insights, and tackling the critical challenge of building trustworthy, reliable AI.
In this session, you will learn:
• Why single-shot queries fail for complex CI and how a multi-step, multi-agent approach yields superior results.
• The essential technical safeguards and “trust factors” required to mitigate AI risks like hallucination, context loss, and sycophancy in a high-stakes CI environment.
• A practical mental model for assessing the true capabilities of any AI tool, enabling you to distinguish genuine innovation from hype and de-risk your own organization’s adoption of AI.

This session explores how primary CI—grounded in direct, real-world insight—can inform timely course correction, future-proof decision-making, and sharpen competitive advantage across the product lifecycle from early stage evaluation to late life cycle management. What’s in it for you? Attendees will gain practical understanding of how to integrate primary CI into strategic execution and how deeper insights and how a four-pronged methodology translates to measurable impact leading to strategic advantage.

The paradox of modern Competitive Intelligence is that more insights can lead to less action.
The constant firehose of news alerts and CI reports overwhelms brand teams, causing strategic paralysis instead of inspiring decisive moves.
This session moves Beyond Autonomous AI to reveal the missing link: the systematic framework for converting a flood of information and insights into clear, executable strategy.
We’ll show you how leading pharmaceutical companies are no longer just delivering actionable intelligence—they’re building “intelligence-to-action” engines.
Drawing on real-world case studies, you will learn how to:
• Bridge the Gap: Implement structured frameworks that connect human and AI-generated insights directly to strategic decision-making.
• Escape the Overload: Design processes that ensure every critical insight has a clear pathway to impact.
• Elevate Your Function: Transform your CI/Insights team from a support service into a core driver of brand strategy.
The winners in this new era won’t be the fastest at collecting data and generating insights. They will be the ones who consistently turn intelligence into action. It’s time to move from information overload to strategic clarity and build a truly unbeatable market strategy.

It is also resource intensive and can leave CI teams bogged down in analysis and unable to provide the strategic guidance that the business demands from them.
In this conversation between Evaluate’s CI lead, Kelly Chamberlain and J&J’s Diana Gowe, we’ll look at the value of getting peer analysis right – even in the era of AI. We’ll discuss how to identify competitive intelligence gaps, and highlight:
• Best practice for creating a peer analysis structure
• How to reduce bias from your analysis
• The strategic benefits for leaders and CI in applying learnings from peer analysis
• How to disseminate CI insights across the business